Eli Lilly looks to startup Verge Genomics to turn AI analysis into new ALS drugs

Alice Zhang, amyotrophic lateral sclerosis, BioPharma, biopharma nl, Daily, deals, Eli Lilly, Pharma, SAN FRANCISCO, SYN, Top Story, Verge Genomics / July 8, 2021

Eli Lilly is partnering with startup Verge Genomics in a move intended to add ALS drugs to its neuroscience pipeline. To date, Verge’s artificial intelligence technology has produced programs internal programs in ALS, Parkinson’s, and frontotemporal dementia.